aibioRegen Biopharma files late-filing notice for its June 30, 2026 quarterly report
Tickers RGBP
Regen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date.
Key facts
- Company
- Regen Biopharma, Inc. (OTC: RGBP)
- News type
- Distress
- Primary source
- Regen Biopharma, Inc. NT 10-Q (2026-08-13)
The notice
Regen Biopharma, Inc. (RGBP) filed a Form 12b-25 notification of late filing on August 13, 2026, covering its quarterly report on Form 10-Q for the period ended June 30, 2026. The company checked the box for the unreasonable effort or expense relief under Rule 12b-25(b).
The reason is stated in a single sentence. The company says it could not complete the 10-Q because of a delay related to the review being performed by its public accountant, and that this delay could not be eliminated without unreasonable effort and expense. The notice does not name the accountant, does not say what part of the review is outstanding, and does not say whether the review has raised any accounting questions.
Under Rule 12b-25, the company says it will file the Form 10-Q no later than the fifth calendar day after the prescribed due date. The notice does not state that due date. If the 10-Q is not filed inside that window, the extension is lost and the report is late without relief.
What the company told the SEC
Part IV of the notice has two answers. The company answered yes to whether all other periodic reports required in the preceding 12 months had been filed. It answered no to whether it expects any significant change in results of operations from the corresponding period of the last fiscal year. The notice therefore gives no sign of a change in results, and it attaches no explanation of one.
The contact named in the notice is David Koos, who signed the form as Chief Executive Officer. The company lists its address as 8697 La Mesa Blvd, Ste C #107, La Mesa, California, and its SEC file number is 333-191725.
The business behind the filing
Regen describes itself as a company that intends to develop regenerative medical applications. It says it intends to license, develop internally or acquire them from others up to the successful completion of Phase I or Phase II clinical trials, and then either sell or license them or advance them to Phase III.
Its lead therapy is HemaXellarate, a cellular composition of autologous stromal vascular fraction derived from adipose tissue, intended for drug-refractory aplastic anemia. The company filed an Investigational New Drug application with the FDA on February 5, 2013. On December 10, 2015, the company says, the FDA told it that it had satisfactorily addressed all clinical hold issues and could start a Phase I trial. The company has also submitted a request for Orphan Drug Designation.
The other programs are earlier. dCellVax uses dendritic cells treated with an siRNA inhibitor of an enzyme called IDO. tCellVax and DiffronC target NR2F6, and DuraCar uses CAR-T cells treated with an shRNA aimed at the same gene. The company says DuraCar and a series of patented small molecules are in preclinical testing. It also says plainly that no clinical trials on its product candidates have commenced, so no conclusions about efficacy can be made. Its statements about its products are, in its words, not predictions of efficacy.
The financial record
The most recent annual figures come from the 10-K filed December 30, 2025. For the fiscal year ended September 30, 2025, Regen reported a net loss of $1.3 million, compared with $668,255 for the prior year. Cash used in operations was $383,591, down from $751,536. Research and development expense fell to $11,725 from $153,685.
Spending on research dropped by a wide margin while the net loss grew. The notice does not explain that gap, and it gives no results for the June 30, 2026 quarter, which is the report now delayed. Readers of a company with no clinical trial under way have no current quarterly numbers to set against the annual figures until the 10-Q arrives.
What comes next
The next event is the 10-Q itself. If it is filed within the five-day window, the notice will have cost little beyond a delay. If it is not, the company will have missed a periodic report deadline despite the extension, and the notice gives no explanation of why the accountant's review is taking longer than planned.